StemCell Therapy

Stem Cell Therapy Market report would come handy to understand the competitors in the market and give an insight into sales, volumes, revenues in the Stem Cell Therapy Industry & will also assists in making strategic decisions. The report also helps to decide corporate product & marketing strategies. It reduces the risks involved in making decisions as well as strategies for companies and individuals interested in the Stem Cell Therapy industry. Both established and new players in Stem Cell Therapy industries can use the report to understand the Stem Cell Therapy market.

In Global Market, the Following Companies Are Covered:

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14849805

Analysis of the Market:

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition. Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use.

In the last several years, global stem cell therapy market developed fast at a average growth rate of 46.81%.

Market Analysis and Insights: Global Stem Cell Therapy Market

In 2019, the global Stem Cell Therapy market size was USD 403.6 million and it is expected to reach USD 1439.9 million by the end of 2026, with a CAGR of 19.7% during 2021-2026.

Global Stem Cell Therapy Scope and Market Size

Stem Cell Therapy market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Stem Cell Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Stem Cell Therapy market is segmented into Autologous, Allogeneic, etc.

Segment by Application, the Stem Cell Therapy market is segmented into Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases, Others, etc.

Regional and Country-level Analysis

The Stem Cell Therapy market is analysed and market size information is provided by regions (countries).

The key regions covered in the Stem Cell Therapy market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape and Stem Cell Therapy Market Share Analysis

Stem Cell Therapy market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Stem Cell Therapy business, the date to enter into the Stem Cell Therapy market, Stem Cell Therapy product introduction, recent developments, etc.

The major vendors include Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix), etc.

This report focuses on the global Stem Cell Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Stem Cell Therapy development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

Stem Cell Therapy Market Breakdown by Types:

Stem Cell Therapy Market Breakdown by Application:

Critical highlights covered in the Global Stem Cell Therapy market include:

The information available in the Stem Cell Therapy Market report is segmented for proper understanding. The Table of contents contains Market outline, Market characteristics, Market segmentation analysis, Market sizing, customer landscape & Regional landscape. For further improving the understand ability various exhibits (Tabular Data & Pie Charts) has also been used in the Stem Cell Therapy Market report.

Get a Sample Copy of the Report @ https://www.360marketupdates.com/enquiry/request-sample/14849805

Reasons for Buy Stem Cell Therapy Market Report:

In the end, Stem Cell Therapy Industry report provides the main region, market conditions with the product price,profit, capacity, production, supply, demand and market growth rateand forecast etc. This report also Present newproject SWOT analysis,investment feasibility analysis, andinvestment return analysis.

Contact Us:

Name: Mr. Ajay More

Email: [emailprotected]

Organization: 360 Market Updates

Phone: +14242530807 / + 44 20 3239 8187

Valencene Market Size Research Report 2020-2026,Comprehensive Study, Development Status, Opportunities, Future Plans, Competitive Landscape and Growth

Enhanced Fire Protection Systems Market Size 2020,Growth Factors, Business Opportunity,Segmentation and Forecast to 2026 Research Reportby implies of360 Market Updates

Antifungal Agents Market Size, Defination, Industry Trends, News andlargeGrowth With Regional Trends By Forecast 2026 Research Reportwith the aid of360 market updates

Rainboots Market Size 2020-2026 Industry Trends, Size, Segments, Competitors Classification, Growth, Up and Down Stream Industry Analysis and Forecast

Ku-Band LNB Market Size & Growth, Sales Revenue, Key Players Analysis, Development Status, Opportunity Assessment and Industry Expansion Strategies 2025 Research Reportwith the aid of360 market updates

ITO Glass Market Size 2020-2026 Research Report by Key Companies, Future Trend, Pipeline Projects, Product, Application, Growth and Regional Forecasts

Perfluoropolyethers Market Size 2020,Business Opportunity, SWOT Analysis, Applications, Trends and Forecast to 2026 Research Reportby360 Market Updates

Visit link:
Stem Cell Therapy Market 2020-2026 | XX% CAGR Projection Over the Next Five Years, Predicts Market Research Future with Market Size & Growth Key...

The study on Adipose Tissue-derived Stem Cell Therapy market provides thorough insights pertaining to major growth drivers, challenges, and opportunities that will influence the industry expansion in the forthcoming years.

According to the research document, the industry is expected to register XX% CAGR over the forecast period (2020-2025), subsequently accruing significant gains by the end of analysis timeframe.

The market is in a disarray due to the lockdowns imposed for limiting the spread of COVID-19 outbreak. In addition to the sudden slump of revenue, some businesses are expected to tackle a plethora of challenges post the pandemic.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/224665

Most of the businesses across various sectors have renewed their budgets to focus on profit gains in upcoming years. Our comprehensive analysis of the business sphere can help stakeholders in making sound decisions to compensate for market uncertainties and support them in building strong contingency plans.

Further, the report provides a granular assessment of the several industry segmentations to convey a deeper understanding of the areas with strong profit potential.

Key inclusions of the Adipose Tissue-derived Stem Cell Therapy market report:

Adipose Tissue-derived Stem Cell Therapy Market segments covered in the report:

Regional segmentation:

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Product types: Autologous Stem Cells and Allogeneic Stem Cells

Applications spectrum: Therapeutic Application and Research Application

Competitive outlook:

Our Market Research Solution Provides You Answer to Below Mentioned Question:

Which are the key factors driving the growth of the industry?

What are the emerging market trends and opportunities for this sector?

What is the future growth trend of this industry?

What is the size of the global and regional sector in terms of volume, size, and revenue?

Which is the most promising region in the global market?

What is the forecasted revenue and volume growth rates of the industry in the coming years?

Which region holds the highest share and what are the market shares of other key regions?

How will each segment and region grow over the years until 2025?

Table of Contents:

Report Overview: It includes major players of the global Adipose Tissue-derived Stem Cell Therapy market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Market Share by Manufacturers: Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Production by Region: Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region: This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Market Size by Type: This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application: Besides an overview of the global Adipose Tissue-derived Stem Cell Therapy market by application, it gives a study on the consumption in the global Adipose Tissue-derived Stem Cell Therapy market by application

Company Profiles: Almost all leading players of the global Adipose Tissue-derived Stem Cell Therapy market are profiled in this section. The analysts have provided information about their recent developments in the global Adipose Tissue-derived Stem Cell Therapy market, products, revenue, production, business, and company.

Key Findings: This section gives a quick look at important findings of the research study.

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/224665

Continue reading here:
Adipose Tissue-derived Stem Cell Therapy Market: Worldwide Industry to Boost in the Period of 2020-2025 - Express Journal

The global Stem Cell Therapy Market research report is a well synchronized synopsis highlighting some of the most significant, real time research analysis that enable quick and efficient business discretion. The report is a quick reference point to make comply with reader understanding of the volatile market situations that collectively steer enormous growth opportunities in the global Stem Cell Therapy Market. The report offers a resourceful outline highlighting various facets that encourage remunerative business decisions in this market. The report draws references of growth-oriented business strategies, concomitant competition, business decisions as well as includes references of dynamic segmentation that collectively ensure steady growth in the global market.

The report categorically sheds ample light on multiply market components such as major trends, persistent challenges as well as barriers and threats that significantly restrict growth in the global Stem Cell Therapy Market. Additionally, to meet with manufacturer needs of opportunity hunting, the report specifically outlines crucial references about major opportunities that steer steady growth and sustainable revenue streams in the global Stem Cell Therapy Market.

Download Sample PDF Brochure with Covid-19 Updates @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=re

This Stem Cell Therapy Market report also strives to provide an essential understanding of the market development from a past and present perspective for accurate forecasting forecasts. In addition, important details of key market players are also included in the report, replicating the growth-oriented business discretion.

COVID-19 Specific Analysis

This up-to-date research report compilation also entices readers to get equipped with ongoing market developments inclusive of unprecedented developments such as COVID-19 outbreak that has crippled businesses and industrial developments in a myriad ways. The report is structured to highlight effective cues for growth oriented business decisions, allowing manufacturers and stakeholders in the Stem Cell Therapy Market to come up with growth friendly strategies and tactics.

Browse full research report @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=re

Understanding regional growth prognosis: global Stem Cell Therapy Market

The next section of the report on the global Stem Cell Therapy Market contains vivid details on regional developments, including details on country-specific events collectively impacting optimistic growth. In addition, important details of key market players are also included in the report, replicating the growth-oriented business discretion. This report also strives to provide an essential understanding of the market development from a past and present perspective for accurate forecasting forecasts.

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

Guide to 5 Guidance for Investing in Reports

1. A thorough end-to-end review and analysis of Stem Cell Therapy Market events and their meaning2. Thorough compilation of a wide range of market segments3. Complete demonstration of industry best practices, careful business decisions, and manufacturer activities driving revenue sustainability in the global Stem Cell Therapy Market4. A complete assessment of the competitive spectrum, including relevant details for key and emerging players5. Accurate review of key dynamics and dominant changes influencing the growth of global Stem Cell Therapy Market.

Make An Enquiry About This Report @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=re

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Excerpt from:
Stem Cell Therapy Market Comprehensive Study COVID19 Impact Analysis 2020-2025 - The Think Curiouser

You may have heard of T cells, but Aleks Radovic-Moreno, Ph.D., Be Biopharmas co-founder, president and director, is betting on B cells as the future of cell therapies.

Our mission is to develop what we see as a new class of cell medicines that have a broad new pharmacology, he said of B cells potential. We think it's a big new white space that's enabled by the rich biology of these cells.

The Cambridge, Massachusetts-based company is capitalizingearly on research by scientists at the University of Washington School of Medicine. With a $52 million series A round in the bank, it'smaking a beeline for the clinic.

Digitize remote site monitoring with Box

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

Why the enthusiasm around B cells? The wayRadovic-Moreno sees it, they'rethe cellular gadget, if you will, that's really good at making large amounts of protein, and they also traffic to where you want them to go."

When we think about it from a drug development standpoint, now you have a system that can make a protein that you want in high quantities in places where you want it to be made, he added.

B cells may also be useful for targeting specific tissues and modulating microenvironments, or [talking] to the cells that are nearby, he said.

One of the biggest challenges to bringing Be Bio to fruition was making the products themselves. Theyre harder to engineer than other cell types thanksto their intrinsic biology, Radovic-Moreno said. Theyre also hard to make correctly and in large quantities, challenges the company only recently overcame.

Those two are the final two bottlenecks that were preventing B cells from being a viable stem cell therapy modality, he said.

RELATED: Q32 debuts with $46M to 'rebalance' innate and adaptive immunity

The applications of B cells include everything from autoimmune diseases to cancer and monogenic disorders, which are caused by variation in a single gene. B-cell therapy could eliminate the need for patients with monogenic disorders who are missing proteins to get biweekly four-hour infusions.

And that's not all. It couldalso eliminate the need for bone marrow transplants in these patients, as well asthe need for a pre-therapy round of chemotherapy, otherwise known as conditioning. For cancer patients who need conditioningahead of a stem cell treatment, the regimencan be deadly up to 10% of the time.

That's extraordinary if you think about a therapy killing patients 10% of the time, Radovic-Moreno said.

Beyond pushing Be'spipeline toward the clinic, the new fundingfrom Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund and other investorswill bankroll potential partnerships and build out the company's team.

The most important thing is to build a great company, hire the best people. We want to be the best B-cell engineers in the world and in history, Radovic-Moreno said. We want to fully capitalize on the timing of this, given that it's a very kind of unusual place to be in this time and age of biotech, where you're sitting right in front of this massive blue wave, big blue ocean of possibilities so big.

Continued here:
Be Biopharma debuts with $52M to advance engineered B-cell therapies - FierceBiotech

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Stem Cell Therapy market.

Trusted Business Insights presents an updated and Latest Study on Stem Cell Therapy Market. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Stem Cell Therapy market during the forecast period.It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Stem Cell Therapy MarketIndustry / Sector Trends

Stem Cell Therapy Market size was valued at USD 7.8 billion in 2018 and is expected to witness 10.2% CAGR from 2021 to 2026.

U.S. Stem Cell Therapy Market Size, By Type, 2018 & 2025 (USD Million)

Rising prevalence of chronic diseases will positively impact the stem cell therapy market growth. Cardiovascular diseases, neurological disorders and other chronic conditions have resulted in high mortality over past few years. Conventional therapeutic methods and treatments are currently replaced due to lack of efficiency and efficacy. Recently developed stem cell therapies are capable of replacing defective cells to treat diseases that has reduced morbidity drastically. Therefore, people have now started relying on stem cell therapy that has long term positive effects.

Advancements in stem cell therapy in developed regions such as North America and Europe have boosted the industry growth. Since past few years, there have been several researches carried out for stem cell therapy. Currently developed stem cell therapies have shown positive outcomes in treatment of leukemia. Similarly, due to advancements in regenerative medicine, several other chronic conditions such as muscular dystrophy and cardiovascular diseases also have been cured. Aforementioned factors have surged the industry growth. However, high cost of allogenic stem cell therapy may hamper the industry growth to some extent.

Market Segmentation, Outlook & Regional Insights: Stem Cell Therapy Market

Stem Cell Therapy Market, By Type

Allogenic stem cell therapy segment held around 39% revenue share in 2018 and it is anticipated to grow substantially during the analysis timeframe. Allogenic stem cell is available as off the shelf therapy and it is easily scalable that helps in providing treatment without delay. Moreover, the procedure includes culturing donor-derived immunocompetent cells that are highly effective in treatment of several diseases. Stem cells obtained in allogenic therapy are free of contaminating tumor cells. This reduces risk for disease recurrence that will surge its demand thereby, stimulating segment growth.

Autologous stem cell therapy segment is estimated to witness 10.1% growth over the forthcoming years. People usually prefer autologous stem cell therapy as it has minimum risk of immunological rejection. However, on introduction of allogenic stem cell therapy, demand for autologous stem cell therapy has declined as it is difficult to scale up. However, there are concerns regarding risk of cross contamination during large scale manufacturing of autologous stem cell lines that will impede segmental growth to some extent.

Stem Cell Therapy Market, By Application

The neurology segment was valued at around USD 1.6 billion in 2018 and it is estimated that it will witness significant growth over the forthcoming years. Stem cells are used to replenish the disrupted neurological cells that help in quick patient recovery. Pluripotent stem cells provide a replacement for cells and tissues to treat Alzheimers, Parkinsons disease, cerebral palsy, amyotrophic lateral sclerosis, and other neurodegenerative diseases. Thus, the pivotal role of stem cells in treating the life-threatening neurological condition will escalate segment growth.

The cardiovascular segment will witness 10% growth over the analysis timeframe. Considerable segmental growth can be attributed to development in stem cell therapies that have enhanced recovery pace in patients suffering from cardiovascular diseases. Recently developed allogeneic stem cell therapies are efficient and easily available that have reduced the mortality rates in cardiovascular patients. Above mentioned factors will propel cardiovascular segment growth in near future.

Stem Cell Therapy Market, By End-users

The hospital segment held over 56% revenue share in 2018 and it is anticipated to grow significantly in near future. The rising preference for stem cell therapies offered by hospitals proves beneficial for business growth. Hospitals have affiliations with research laboratories and academic institutes that carry out research activities for developing stem cell therapies. On the introduction and approval of any novel stem therapy, hospitals implement it immediately. Associations with research and academic institutes further help hospitals to upgrade its stem cell treatment offerings that positively impact the segmental growth.

The clinics segment is expected to grow at around 10% during the forecast timeframe. Clinics specializing in providing stem cell therapies are well-equipped with advanced medical devices and superior quality reagents required for imparting stem cell therapies. However, as clinics offer specialized stem cell therapies, their treatment cost is much higher as compared to hospitals that may reduce its preference.

Stem Cell Therapy Market, By Region

North America stem cell therapy market held around 41.5% revenue share in 2018 and it is estimated to grow substantially in near future. Increasing the adoption of novel stem cell therapies will prove beneficial for regional market growth. Moreover, favorable government initiatives have a positive impact on regional market growth. For instance, the government of Canada has initiated Strategic Innovation Fund Program that invests in research activities carried out for stem cell therapies enabling development in stem cell therapy. Above mentioned factors are expected to drive the North America market growth.

Asia Pacific stem cell therapy market is anticipated to witness 10.8% growth in the near future owing to increasing awareness amongst people pertaining to the benefits of advanced stem cell therapies. Additionally, favorable initiatives undertaken by several organizations will promote industry players to come up with innovative solutions. For instance, according to Pharma Focus Asia, members of the Asia-Pacific Economic Cooperation collaborated with Life Sciences Innovation Forum to involve professionals having expertise in stem cell therapies from academia and research centers to promote developments in stem cell research. Thus, growing initiatives by organizations ensuring the availability of new stem cell therapies will foster regional market growth.

Latin America Stem Cell Therapy Market Size, By Country, 2025 (USD Million)

Key Players, Recent Developments & Sector Viewpoints: Stem Cell Therapy Market

Key industry players in the stem cell therapy market include Astellas Pharma Inc, Cellectis, Celyad, Novadip Biosciences, Gamida Cell, Capricor Therapeutics, Cellular Dynamics, CESCA Therapeutics, DiscGenics, OxStem, Mesoblast Ltd, ReNeuron Group, and Takeda Pharmaceuticals. Chief industry players implement several initiatives such as mergers and acquisitions to sustain market competition. Also, receiving approvals for stem cell therapy products from regulatory authorities fosters the companys growth. For instance, in March 2018, the European Commission approved Takedas Alofisel that is off-the-shelf stem cell therapy. Product approval will help the company to gain a competitive advantage and capture market share.

Stem Cell Therapy Industry Viewpoint

The stem cells industry can be traced back to the 1950s. In 1959 first animals were made by in-vitro fertilization by preserving the stem cells. Till 2000, research was being carried out on stem cells to study its therapeutic effect. In 2000, fund allocations were made to research on cells derived from aborted human fetuses. In the same year, scientists derived human embryonic stem cells from the inner cell mass of blastocytes. Later, in 2010, clinical trials for human embryonic stem cell-based therapy were initiated. As technology progressed, stem cell therapy for treating cancer was developed. However, due to ethical issues, the use of stem cells for curing diseases witnessed slow growth for a few years. But as the regulatory scenario changed, people started preferring stem cell therapies due to its better efficacy. Stem cell therapy is in the developing stage and has numerous growth opportunities in developing economies with a high prevalence of chronic diseases.

Key Industry Development

In September 2020, Takeda Pharmaceutical Company Limited announced the expansion of its cell therapy manufacturing capabilities with the opening of a new 24,000 square-foot R&D cell therapy manufacturing facility at its R&D headquarters in Boston, Massachusetts. The facility provides end-to-end research and development capabilities and will accelerate Takedas efforts to develop next-generation cell therapies, initially focused on oncology with the potential to expand into other therapeutic areas.

The R&D cell therapy manufacturing facility will produce cell therapies for clinical evaluation from discovery through pivotal Phase 2b trials. The current Good Manufacturing Practices (cGMP) facility is designed to meet all U.S., E.U., and Japanese regulatory requirements for cell therapy manufacturing to support Takeda clinical trials around the world.

The proximity and structure of Takedas cell therapy teams allow them to quickly apply what they learn across a diverse portfolio of next-generation cell therapies including CAR NKs, armored CAR-Ts, and gamma delta T cells. Insights gained in manufacturing and clinical development can be quickly shared across global research, manufacturing, and quality teams, a critical ability in their effort to deliver potentially transformative treatments to patients as fast as possible.

Takeda and MD Anderson are developing a potential best-in-class allogeneic cell therapy product (TAK-007), a Phase 1/2 CD19-targeted chimeric antigen receptor-directed natural killer (CAR-NK) cell therapy with the potential for off-the-shelf use being studied in patients with relapsed or refractory non-Hodgkins lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Two additional Phase 1 studies of Takeda cell therapy programs were also recently initiated: 19(T2)28z1xx CAR T cells (TAK-940), a next-generation CAR-T signaling domain developed in partnership with Memorial Sloan Kettering Cancer Center (MSK) to treat relapsed/refractory B-cell cancers, and a cytokine and chemokine armored CAR-T (TAK-102) developed in partnership with Noile-Immune Biotech to treat GPC3-expressing previously treated solid tumors.

Takedas Cell Therapy Translational Engine (CTTE) connects clinical translational science, product design, development, and manufacturing through each phase of research, development, and commercialization. It provides bioengineering, chemistry, manufacturing, and control (CMC), data management, analytical, and clinical and translational capabilities in a single footprint to overcome many of the manufacturing challenges experienced in cell therapy development.

Key Insights Covered: Exhaustive Stem Cell Therapy Market1. Market size (sales, revenue and growth rate) of Stem Cell Therapy industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Stem Cell Therapy industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Stem Cell Therapy industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Stem Cell Therapy industry.

Research Methodology: Stem Cell Therapy Market

Looking for more? Check out our repository for all available reports on Stem Cell Therapy in related sectors.

Quick Read Table of Contents of this Report @ Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See original here:
Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19) - Eurowire

The report provides study at global and regional level to provide comprehensive value market analysis for the years (2017 & 2018 Historic Years, 2019 Base Year and 2020-2027 Forecast Period). The Platelet Rich Plasma & Stem Cell Alopecia Treatment Market research report is a wide-ranging study of current trends, market growth drivers, and restraints. Each market segment is broadly analyzed at a powdered level by region (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America) to provide thorough information on the global and regional level.

Some of the key players in this market include

Download Sample PDF Brochure of this research study at https://www.theinsightpartners.com/sample/TIPRE00004413/

The global platelet rich plasma & stem cell alopecia treatment market is segmented on the basis of treatment and end user. Based on treatment, the market is segmented as, stem cell therapy and platelet rich plasma therapies. The platelet rich plasma & stem cell alopecia treatment market is categorized based on end user such as, dermatology clinics, hospitals and other end users.

The segmentation in this research study has been finalized post in-depth secondary research and extensive primary research. In addition, the market is also segmented on the basis of technology offered by the leading participants in the industry in order to understand widely used market specific terminologies. Thus, we have incorporated the segments of the research and have finalized the market segmentation.

The Insight Partners Platelet Rich Plasma & Stem Cell Alopecia Treatment Market Research Report Scenario includes:

Order a copy of this research study at https://www.theinsightpartners.com/buy/TIPRE00004413/

The report also covers a detailed chapter of the analysis on COVID-19 impact on this market at global and regional level in our final reports.

This research provides detailed information regarding the major factors influencing the growth of the Platelet Rich Plasma & Stem Cell Alopecia Treatment Market in Global and Regional Level (drivers, restraints, opportunities, and challenges), forecast of the market size, in terms of value, market share by region and segment; regional market positions; segment and country opportunities for growth; New product developments, strengths and weaknesses, brand portfolio; Marketing and distribution strategies; challenges and threats from current competition and prospects; Key company profiles, SWOT, product portfolio and growth strategies.

ABOUT US:

The Insight Partners is a one stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Our research model is very simple. We believe in client servicing and delivering best quality to our customers. Through our research content, we are making sure that our customers get value of their money along with better quality data and analysis.

Our research content is majorly focused towards market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis etc. We provide detailed break-up of segmentation in terms of geography, technology, product and services etc.; which helps our clients to get a deeper analysis on various research topics.

Contact US:

If you have any queries about this report or would like further information, please contact us:

North America: +1 646 491 9876

Asia-Pacific: +91 20 6727 8686

Email: [emailprotected]

Read the original here:
Platelet Rich Plasma & Stem Cell Alopecia Treatment Market 2020: Reporting and Evaluation of Recent Industry Developments - Eurowire

Global Stem Cell Therapy Market Research Assessment and Forecast 2020 2028 offers an assessment of the global Stem Cell Therapy market and a forecast of market demand by type and segment of end users. This study offers a comprehensive industry assessment as it includes statistically validated and validated industry market data, facts, critical findings, and historical data. It also contains predictions made using an appropriate set of methodologies to obtain accurate values. Market analysis offers information according to the categories identified through market segmentation, which includes product type, geography and applications.

Get a Sample PDF copy of the Stem Cell Therapy Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/691?utm_source=bh

Provides a worldwide analysis of Stem Cell Therapy market growth for both regional and global markets, including an understanding of business strategy, development trends, opportunities and development status of important regions.

The study provides quantitative information on key industry trends, market size (value and volume) and development of each end-user segment of Stem Cell Therapy, import / export of Stem Cell Therapy by region, production volume and main country. Historical and future consumption trends, as well as market innovations, as well as the challenges faced by major Stem Cell Therapy manufacturers as well as end users, are suggested.

Browse the complete report Along with TOC @ https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market?utm_source=bh

Each market participant included in the Stem Cell Therapy market study is ranked according to its manufacturing coverage, market share, existing and new launches, ongoing R&D projects and business strategies. In addition, market research for Stem Cell Therapy provides an assessment of strengths, weaknesses, opportunities and threats (SWOT). The report assesses and explores the prospects for the global platelet market, including sales, production and use, as well as historical data and projections.

Stem Cell Therapy Market Segmentation

Type Analysis of Stem Cell Therapy Market:

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Applications Analysis of Stem Cell Therapy Market:

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

Market research monitors the global situation and explains how the industry will create promising profit margins for manufacturers in the post-COVID-19 crisis. The market research aims to offer further information on the economic downturn, the latest scenario and the impact of COVID-19 on the industry as a whole.

Scope of the global Stem Cell Therapy Market Report:

This research covers detailed manufacturer data such as shipment, price, gross margin, interview record, revenue, business distribution, etc. This data helps the user to get to know the competition better. The report also includes all regions and countries of the world, showing the complex status of regional growth such as market size, volume and value, and price data.

Likewise, the study also covers segment data, including segment type, market segment, channel segment, and so on, which contains different market segment sizes, both in value and volume. In addition, it covers consumer data from different industries, which is very important for service providers.

Analyzing the Investment Potential of the Global Stem Cell Therapy Market Report

The report hovers across the past and current dynamics to deduce significant developments in the aforementioned market, thus effectively encouraging agile business outcome The report also is a ready-to-refer documentation that entails substantial information featuring the developments across segments and their role in growth optimization Systematic R&D activities and concomitant resource planning are thoroughly touched upon in this report featuring the development graph in global Stem Cell Therapy market. The report also ensures investor participation towards directing manufacturer and vendor activities in a bid to achieve significant competitive edge. Market based developments are also accurately sectioned in both value-based volume-based calculations to thoroughly encourage reader understanding and subsequent growth potential in global Stem Cell Therapy market.

Make an Enquiry for purchasing this Report @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691?utm_source=bh

About Us :

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

Continued here:
Stem Cell Therapy Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast 2026 - The Think Curiouser

The globalRheumatoid Arthritis Stem Cell Therapy marketstudy presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Rheumatoid Arthritis Stem Cell Therapy market player in a comprehensive way. Further, the Rheumatoid Arthritis Stem Cell Therapy market report emphasizes the adoption pattern of the Rheumatoid Arthritis Stem Cell Therapy across various industries.Request Sample Reporthttps://www.factmr.com/connectus/sample?flag=S&rep_id=1001The Rheumatoid Arthritis Stem Cell Therapy market report highlights the following players:The global market for rheumatoid arthritis stem cell therapy is highly fragmented. Examples of some of the key players operating in the global rheumatoid arthritis stem cell therapy market include Mesoblast Ltd., Roslin Cells, Regeneus Ltd, ReNeuron Group plc, International Stem Cell Corporation, TiGenix and others.

The Rheumatoid Arthritis Stem Cell Therapy market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.Important regions covered in the Rheumatoid Arthritis Stem Cell Therapy market report include:

North America (U.S., Canada)Latin America (Mexico, Brazil)Western Europe (Germany, Italy, U.K., Spain, France, Nordic countries, BENELUX)Eastern Europe (Russia, Poland, Rest Of Eastern Europe)Asia Pacific Excluding Japan (China, India, Australia & New Zealand)JapanMiddle East and Africa (GCC, S. Africa, Rest Of MEA)

The Rheumatoid Arthritis Stem Cell Therapy market report takes into consideration the following segments by treatment type:

Allogeneic Mesenchymal stem cellsBone marrow TransplantAdipose Tissue Stem Cells

The Rheumatoid Arthritis Stem Cell Therapy market report contain the following distribution channel:

HospitalsAmbulatory Surgical CentersSpecialty ClinicsHave Any Query? Ask our Industry Experts-https://www.factmr.com/connectus/sample?flag=AE&rep_id=1001

Buy the report at a discounted rate!!! Exclusive offer!!!

The Rheumatoid Arthritis Stem Cell Therapy market report offers a plethora of insights which include:

Changing consumption pattern among individuals globally.Historical and future progress of the global Rheumatoid Arthritis Stem Cell Therapy market.Region-wise and country-wise segmentation of the Rheumatoid Arthritis Stem Cell Therapy market to understand the revenue, and growth lookout in these areas.Accurate Year-on-Year growth of the global Rheumatoid Arthritis Stem Cell Therapy market.Important trends, including proprietary technologies, ecological conservation, and globalization affecting the global Rheumatoid Arthritis Stem Cell Therapy market.

The Rheumatoid Arthritis Stem Cell Therapy market report answers important questions which include:

Which regulatory authorities have granted approval to the application of Rheumatoid Arthritis Stem Cell Therapy in Health industry?How will the global Rheumatoid Arthritis Stem Cell Therapy market grow over the forecast period?Which end use industry is set to become the leading consumer of Rheumatoid Arthritis Stem Cell Therapy by 2028?What manufacturing techniques are involved in the production of the Rheumatoid Arthritis Stem Cell Therapy?Which regions are the Rheumatoid Arthritis Stem Cell Therapy market players targeting to channelize their production portfolio?Get Full Access of the Report @https://www.factmr.com/report/1001/rheumatoid-arthritis-stem-cell-therapy-market

Pertinent aspects this study on the Rheumatoid Arthritis Stem Cell Therapy market tries to answer exhaustively are:

What is the forecast size (revenue/volumes) of the most lucrative regional market? What is the share of the dominant product/technology segment in the Rheumatoid Arthritis Stem Cell Therapy market? What regions are likely to witness sizable investments in research and development funding? What are Covid 19 implication on Rheumatoid Arthritis Stem Cell Therapy market and learn how businesses can respond, manage and mitigate the risks? Which countries will be the next destination for industry leaders in order to tap new revenue streams? Which new regulations might cause disruption in industry sentiments in near future? Which is the share of the dominant end user? Which region is expected to rise at the most dominant growth rate? Which technologies will have massive impact of new avenues in the Rheumatoid Arthritis Stem Cell Therapy market? Which key end-use industry trends are expected to shape the growth prospects of the Rheumatoid Arthritis Stem Cell Therapy market? What factors will promote new entrants in the Rheumatoid Arthritis Stem Cell Therapy market? What is the degree of fragmentation in the Rheumatoid Arthritis Stem Cell Therapy market, and will it increase in coming years?Why Choose Fact.MR?

Fact.MR follows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

Originally posted here:
Potential impact of Covid-19 on Rheumatoid Arthritis Stem Cell Therapy Market Growth and Demand, Concludes Fact.MR - The Cloud Tribune

Amniotic Fluid Stem Cell Therapy Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The report provides both quantitative and qualitative information of global Amniotic Fluid Stem Cell Therapy market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Amniotic Fluid Stem Cell Therapy is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Amniotic Fluid Stem Cell Therapy market was valued at USD _ million/billion.

This research report based on Amniotic Fluid Stem Cell Therapy market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Amniotic Fluid Stem Cell Therapy market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Amniotic Fluid Stem Cell Therapy industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/23101

Amniotic Fluid Stem Cell Therapy Market Overview:

The Research projects that the Amniotic Fluid Stem Cell Therapy market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.

Leading manufacturers of Amniotic Fluid Stem Cell Therapy Market:

key players operating in global amniotic fluid stem cell therapy market are Stem Shot, Provia Laboratories LLC, Thermo Fisher Scientific Inc. Mesoblast Ltd., Roslin Cells, Regeneus Ltd. etc. among others.

The report covers exhaustive analysis on:

Regional analysis includes

Report Highlights:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/23101

Some important highlights from the report include:

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/23101

The Questions Answered by Amniotic Fluid Stem Cell Therapy Market Report:

And Many More.

See original here:
Lucrative Opportunities in North America to Propel the Growth of the Amniotic Fluid Stem Cell Therapy Market 2018 2026 - TechnoWeekly

An up-to-date intelligence study by Global Adipose Derived Stem Cell Therapy Market Growth (Status and Outlook) 2020-2025 provides the present scenario of the market and offers a comparative assessment of the market. The report provides historical data, significance, statistical data, size & share, market price & demand, business overview, market analysis by product and market trends by key players. It detects that the global Adipose Derived Stem Cell Therapy market by technological advancements and the presence of a large number of players, who are making the competitive landscape distributed. The report further highlights current growth factors, market threats, attentive opinions, and competitive analysis of major Adipose Derived Stem Cell Therapy market players, value chain analysis, and future roadmap.

Competitiveness:

The Adipose Derived Stem Cell Therapy market is fragmented and is characterized by the presence of key vendors and other prominent vendors. Key vendors are trying to maintain themselves in the global Adipose Derived Stem Cell Therapy market, whereas, regional vendors are focusing on product offerings to establish themselves in the market. Vendors are providing a different range of product lines intensifying the competitive scenario.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketandresearch.biz/sample-request/150958

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Market Potential:

The market vendors have been forecasted to obtain new opportunities as there has been an increased emphasis on spending more on the work of research and development by many of the manufacturing companies. Additionally, many of the market participants are anticipated to make a foray into the emerging economies that are yet to be explored so as to find new opportunities. The global Adipose Derived Stem Cell Therapy market has gone through rapid business transformation by good customer relationships, drastic and competitive growth, significant changes within the market, and technological advancement in the worldwide market.

Topmost list manufacturers/ key player/ economy by business leaders leading players of the market are: AlloCure, Tissue Genesis, Antria, Cellleris, Corestem, Celgene Corporation, Mesoblast, Cytori Therapeutics, Pluristem Therapeutics, Intrexon, Lonza, BioRestorative Therapies, Pluristem Therapeutics, iXCells Biotechnologies, Cyagen, Celltex Therapeutics Corporation,

Geographically, this report studies market share and growth opportunity in the following key regions: Americas (United States, Canada, Mexico, Brazil), APAC (China, Japan, Korea, Southeast Asia, India, Australia), Europe (Germany, France, UK, Italy, Russia), Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

On the basis of product segment, this report covers: Autologous Stem Cells, Allogeneic Stem Cells,

On the basis of Application segment, this report covers: Therapeutic Application, Research Application,

ACCESS FULL REPORT: https://www.marketandresearch.biz/report/150958/global-adipose-derived-stem-cell-therapy-market-growth-status-and-outlook-2020-2025

Important Take-Away:

Moreover, the report has covered the PEST analysis by region and key economies across the globe, PORTERs analysis, and detailed SWOT analysis of key players to analyze their strategies. It guides companies to make effective business strategy decisions by knowing the global Adipose Derived Stem Cell Therapy market conditions and sentiment within the market. The report serves to adjust investment allocation by outlining key focus areas of the industry.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketandresearch.biz

Other Related Reports Here:

Global Myristamine Oxide Market 2020 Industry Growth Analysis by Key Players, Segments, Competitive Landscape and Forecast to 2026

Global Rivastigmine Tartrate Market 2020 Emerging Trend, Top Companies, Industry Demand, Business Review and Regional Analysis by 2026

Global 3-Methoxy-3-Methyl-1-Butanol Market 2020 Industry Status and Outlook, Competitive Landscape and Growth by 2026

Global Sodium Tetra Sulphide Market 2020 Industry Analysis, Size, Share, Growth, Trend and Forecast to 2026

Global 3-Chloropivaloyl Chloride Market 2020 by Key Players, Regions, Type and Application, Forecast to 2026

Continued here:
Global Adipose Derived Stem Cell Therapy Market 2020 Demand, Business Growing Strategies, Industry Segmentation and Forecast 2025 - TechnoWeekly

Treatment with otilimab, a monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), is well tolerated, despite optimal exposure, and may improve synovitis in patients with active rheumatoid arthritis (RA), according to study results published in Lancet Rheumatology.

Previous studies have reported that GM-CSF can act as a proinflammatory cytokine and has an important role in a broad range of immune-mediated conditions, making it a valuable therapeutic target in patients with RA. The objective of the current mechanistic phase 2a study was to determine the effect of otilimab on the GM-CSF-chemokine (C-C motif) ligand 17 (CCL17) axis and synovitis in patients with RA.

The multicenter, randomized, placebo-controlled study (ClinicalTrials.gov Identifier: NCT02799472) included adult patients with RA from across 9 sites in the United States, Poland, and Germany. Participants were randomly assigned to receive either 180 mg of subcutaneous otilimab or placebo. The primary outcome was change over time in 112 biomarkers. Secondary end points included change from baseline in synovitis, osteitis, and erosion assessed by the RA magnetic resonance imaging (MRI) Scoring (RAMRIS) system, RA MRI Quantitative (RAMRIQ) score, and safety evaluation.

A total of 39 patients with RA who were randomly assigned to receive otilimab (n=28) or placebo (n=11) were included in the final cohort. Weekly subcutaneous injections of otilimab 180 mg or placebo were administered for 5 weeks, then every other week until week 10, followed by a 12-week safety follow-up.

Results showed that mean serum concentrations of the GM-CSF-otilimab complex peaked at week 4 (138.4 ng/L), but reduced from week 6 to 12, with CCL17 concentrations decreasing and then returning to baseline at week 12 (least-squares mean ratios at weeks 2, 4, 6, and 8 were 0.65, 0.68, 0.78, and 0.68, respectively). In the placebo group, no significant changes in CCL17 concentrations were noted. There were also no differences between groups for all other biomarkers.

Results from imaging measures of synovitis showed a reduction from baseline to week 12 in patients who received otilimab. Differences in MRI outcomes were minimal, and a trend for reduced synovitis and osteitis was seen early during active treatment, but not at 12 weeks after the treatment was stopped. The RAMRIS synovitis score showed a least-squares mean change from baseline of -1.3 (SE, 0.6) in the otilimab group and a mean change of 0.8 (SE, 1.2) in the placebo group (P =.11). The RAMRIQ synovitis score showed a least-squares mean change from baseline of -1417.0 L in the otilimab group and -912.3 L with placebo (P =.75).

All adverse events were reported to be mild or moderate, and the number of adverse events was similar in the otilimab and placebo groups (39% and 36%, respectively). The most common adverse event was cough (7%) in the active treatment group and pain in extremity (18%) and RA (18%) in the placebo group. There were no serious adverse events or deaths.

The study had several limitations, including the relatively small sample size, imbalanced baseline disease-modifying antirheumatic drug use among treatment groups, and the determination of the RAMRIS synovitis score based on assessment by a single radiologist.

The findings of this study support the rationale for the further clinical development of otilimab as a treatment option for patients with [RA]. Additionally, the effect of otilimab on CCL17 indicates that CCL17 shows promise as a pharmacodynamic biomarker for otilimab in future studies, the researchers concluded.

Disclosure: This clinical trial was supported by GlaxoSmithKline. Please see the original reference for a full list of authors disclosures.

Genovese MC, Berkowitz M, Conaghan PG, et al. MRI of the joint and evaluation of the granulocytemacrophage colony-stimulating factorCCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study. Lancet Rheumatol. Published online October 7, 2020. doi:10.1016/s2665-9913(20)30224-1

Excerpt from:
Otilimab Well Tolerated and May Improve Synovitis in Active Rheumatoid Arthritis - Rheumatology Advisor

Background:Rheumatoid arthritis (RA) is a rheumatic disease characterized by erosive synovitis and polyarthritis. Exercise is known to improve many symptoms in RA patients.

Aim:This study was designed to compare the effects of pilates exercises, aerobic exercises, and combined training including pilates with aerobic exercises on fatigue, depression, aerobic capacity, pain, sleep quality, and quality of life.

Methods:Thirty voluntary RA patients were included in this study. Patients were divided into three groups equally, and treatment was applied to each group for 8 weeks. Pilates exercises were practiced to the first group, aerobic exercises were practiced to the second group, and combined training was performed to the third group. Fatigue, depression, aerobic capacity, pain, sleep quality, and quality of life were evaluated using Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), 6-minute walk test (6MWT), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburg Sleep Quality Index (PSQI), and Rheumatoid Arthritis Quality of Life (RAQoL), respectively.

Results:The results of the present study showed significant improvements for the first group on fatigue, depression, aerobic capacity, and quality of life (p < 0.05). Improvements in all parameters except for pain were obtained for the second and third groups (p < 0.05). In addition, there was no statistically significant difference among the treatment groups in assessments (p > 0.05).

Conclusion:Pilates exercises may have similar effects to aerobic exercises in patients with RA. Addition of clinical pilates exercises to the routine treatment of RA may enhance the success of rehabilitation. Trial registrationNCT03836820.

Keywords:Aerobic exercises; Fatigue; Pilates exercises; Rheumatoid arthritis.

Link:
Comparison of the effectiveness of pilates exercises, aerobic exercises, and pilates with aerobic exercises in patients with rheumatoid arthritis -...

TRUMBULL, Conn., Oct. 22, 2020 /PRNewswire/ --ZetrOZ Systems, developers of sustained acoustic medicine (SAM), an FDA-cleared home-use ultrasound device that helps reduce pain associated with tendon, ligament, and muscle injuries, has received funding from the National Institute of Health (NIH) to find a way to reduce arthritic pain utilizing non-surgical, non-narcotic technology.

Arthritic pain has been primarily managed by nonsteroidal anti-inflammatory drugs (NSAIDs), namely diclofenac. Diclofenac, which is administered topically, is limited in its efficacy due to its limited ability to penetrate the skin. New findings from researchers at the University of Cincinnati show SAM technology's ability to deliver NSAIDs locally and effectively, demonstrating 380% enhanced delivery compared to existing technology for the treatment of joint pain.

"Targeted and localized drug delivery is the holy grail for many therapeutic agents, and this has been demonstrated with small-molecule therapeutics, combined with our latest sam 2.0," says Dr. George Lewis, CEO of ZetrOZ Systems. "The research community is excited by the findings, as it has broad implications for the local delivery of therapeutic agents without the need for oral delivery."

The study published in the Journal of Therapeutic Delivery Vol 11. NO 6.investigated the use of sam 2.0, "a multi-hour, wearable, localized, sonophoresis transdermal drug delivery device for the penetration enhancement of diclofenac through the skin." The use of sam 2.0 medical technology resulted in increased delivery of diclofenac by 380% and increased depth of penetration of the skin by 32%. Findings concluded that sustained acoustic medicine can be used as an effective transdermal drug-delivery device for nonsteroidal anti-inflammatory drugs.

"Our collaborations with the top research institutions such as the University of Cincinnati foster continuous innovation on sustained acoustic medicine in the treatment of chronic pain," adds Lewis.

About ZetrOZ Systems

ZetrOZ Systems is an FDA cGMP and ISO 13585 medical technology company headquartered in the southern coastal region of Connecticut. The organization also has manufacturing facilities across the United States. ZetrOZ Systems produced UltrOZ, samSport and samPro 2.0 to provide safe and effective treatment options for prevalent conditions such as arthritis. Learn more at zetroz.comand samrecover.com.

Media Contact: [emailprotected]

Related Images

sam-2-0-medical-technology.jpg SAM 2.0 medical technology featured in the Journal of Therapeutic Delivery for the treatment of chronic arthritis pain

SOURCE ZetrOZ Systems

See the rest here:
ZetrOZ Receives Funding from the National Institute of Health to Find New Ways to Reduce Arthritic Pain for Over 60 Million Americans Using...

CHANDAN KHANNA/AFP/Getty Images A medic prepares to transfer a patient on a stretcher from an ambulance outside of Emergency at Coral Gables Hospital where Coronavirus patients are treated in Coral Gables near Miami, on July 30, 2020. - Florida has emerged as a major new epicenter of the US battle against the disease, with confirmed cases recently surpassing New York and now second only to California. The state toll has leapt over the past week and more than 6,500 people have died from the disease there, according to health officials. More than 460,000 people have been infected with the virus in Florida, which has a population of 21 million, and a quarter of the state's cases are in Miami. The US has tallied a total of 151,826 deaths from COVID-19, making it the hardest-hit country in the world. (Photo by CHANDAN KHANNA / AFP) (Photo by CHANDAN KHANNA/AFP via Getty Images)

Tocilizumab, a repurposed rheumatoid arthritis drug once considered a promising treatment for hospitalized patients with Covid-19, generally did not increase patients' chances of survival or help them get better faster, according to three trials published this week.

However, a fourth trial did find the drug increased the chances of survival, but because it was an observational study, the results are considered less definitive.

Three of the trials were published Tuesday in the Journal of the American Medical Association and the other was published Wednesday in the New England Journal of Medicine.

While this leaves the picture for tocilizumab use a bit muddy, the studies taken together show the drug isn't a magic bullet that should be used in all hospitalized patients with Covid-19, but they leave the door open for possible use in specific patient groups.

"It is possible that forthcoming results from other randomized trials will help us identify specific groups of people who will benefit. However, growing evidence supports current guidelines, which recommend against tocilizumab use outside of clinical trials," Dr. Jonathan Parr told CNN.

Parr, an assistant professor in the division of infectious diseases at the University of North Carolina at Chapel Hill, wrote an editorial that was published alongside the three studies in JAMA.

Tocilizumab, sold under the brand name Actemra and used to treat rheumatoid arthritis, blocks interleukin-6, a molecule that produces inflammation.

Earlier in the pandemic, the drug became widely used in the United States after reports from China and Europe appeared to show it helped very ill patients who experienced a so-called cytokine storm by extinguishing the out-of-control inflammation that developed in response to the coronavirus.

However, those early reports were mostly observational, meaning they took existing data and analyzed it as opposed to designing a trial specifically to assess tocilizumab.

But now the results from trials designed to look at the drug prospectively are beginning to come in.

The first of the three JAMA studies found that hospitalized patients in Italy who were not yet in intensive care and who received tocilizumab fared no better than those who received standard care. The trial was stopped early due to "futility."

A similar study in France found that tocilizumab may have led to slight improvements by day 14 over usual care, but there were no differences in survival by day 28.

The third study found that the risk of in-hospital death was about 30% lower in US patients receiving tocilizumab within the first two days of ICU admission compared to those who didn't get the drug.

But because it was an observational trial there could be factors that affected the results other than how well the drug itself worked.

"We specifically studied tocilizumab administration in very sick patients, all of whom required ICU level of care. In contrast, the [other two trials] studied patients with much milder illness severity," said Dr. Shruti Gupta of Brigham and Women's Hospital in Boston, who led the study team.

Dr. David Leaf, the trial's senior author, added, "We focused on early use of tocilizumab -- within the first two days of ICU admission. This may be the key to tocilizumab's efficacy -- administering it prior to the occurrence of irreversible organ injury," he said in an email.

Gupta said their findings need confirmation by a large randomized, controlled trial.

The fourth study, published Wednesday in the New England Journal of Medicine, used the gold standard of trial design-- it's a randomized, double-blind, placebo control trial.

It enrolled 243 patients from seven Boston-area hospitals who were admitted with Covid-19 at the height of the surge in that region.

"The primary goal of the trial was to determine if tocilizumab, administered intravenously at a moderate stage of the patients' disease, could prevent progression to intubation or death," said Dr. John H. Stone, lead study author and director of Clinical Rheumatology at Massachusetts General Hospital, told CNN via email.

But the findings were not encouraging for the use of tocilizumab.

"Our data do not support the concept that early IL-6 receptor blockade is an effective treatment strategy in moderately ill patients hospitalized with Covid-19 infection," said Stone.

Results show that the chances of intubation or death were about similar in both groups and patients in both groups essentially took the same amount of time to discontinue supplemental oxygen.

So, where does that leave tocilizumab?

"Tocilizumab may still have a role in COVID-19. Several large trials are expected to come out soon that will tell us more about how and when it should be used, if at all," said Parr, noting that it "shouldn't be taken off the table completely, but we need more convincing evidence before using it routinely."

Stone agreed that the drug may still benefit other patient groups, but he stressed the importance of doing these trials.

"An important take-away point from our trial and the overall experience with IL-6 receptor blockade is that any such approach to the treatment of COVID-19 must be subjected to randomized, blinded trials," he said, adding that the trials should be done "before the adoption of widespread use."

View original post here:
Rheumatoid arthritis drug tocilizumab falls short as treatment for hospitalized Covid-19 patients in three studies - msnNOW

New Study Reports Rheumatoid Arthritis Stem Cell Therapy Market 2020 Global Market Opportunities, Challenges, Strategies and Forecasts 2026 has been Added on Fact.MR.OverviewStarting from the fundamental details, the report provides a complete overview of the industry along with a proper market profile. The details provided here about the crucial technologies used for manufacturing and product management purpose makes it easier to have a thorough insight into the Global Rheumatoid Arthritis Stem Cell Therapy Market. Based on the information obtained, the market has been segmented into various categories. It predicts the growth rate of the Global Rheumatoid Arthritis Stem Cell Therapy Market in between the forecasted period, having a base year as 2020.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

This report focuses Global Rheumatoid Arthritis Stem Cell Therapy market, it covers details as following:Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Market DynamicsThe report identifies all the key aspects that drive the super-fast growth of the international Global Rheumatoid Arthritis Stem Cell Therapy Market. In this context, it identifies the crucial aspects regarding the pricing part of the concerned product. It analyses the market value of each of the products and services as well in the report, including the various kinds of volume trends. Prime aspects that are covered in this report range from the effect of growing population at international level, accelerating technological growth, and the analysis of level of demand and supply as evident in the Global Rheumatoid Arthritis Stem Cell Therapy Market. The report also covers extensive studies regarding various effects in relation to the initiatives taken by the government and the competitive platform that is there in the Global Rheumatoid Arthritis Stem Cell Therapy Market in between the forecasted period. Segmental AnalysisThe report does thorough segmentation of international Global Rheumatoid Arthritis Stem Cell Therapy Market upon taking various factors associated with the growth of the market. It does a thorough regional segmentation. These segmentation based studies are done with an intention of achieving a thorough and specific insight of the Global Rheumatoid Arthritis Stem Cell Therapy Market. The report does a regional analysis of the key zones of the world, starting from the US, North America, Latin America, Middle East & Africa, and Asia. Modes of researchThe research being done by experienced experts has done a comprehensive analysis of Global Rheumatoid Arthritis Stem Cell Therapy Market based on Porters Five Force Model, taking the assessment period between 2020-2026 into account. Additionally, a deep SWOT analysis is done to facilitate quick decision making for the associated people in the Global Rheumatoid Arthritis Stem Cell Therapy Market.

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Report covers:Comprehensive research methodology of Global Rheumatoid Arthritis Stem Cell Therapy Market.This report also includes detailed and extensive market overview with gap analysis, historical analysis & key analyst insights.An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.Analysis of regional regulations and other government policies impacting the Global Rheumatoid Arthritis Stem Cell Therapy Market.Insights about market determinants which are stimulating the Global Rheumatoid Arthritis Stem Cell Therapy Market.Detailed and extensive market segments with regional distribution of forecasted revenuesExtensive profiles and recent developments of market players

Read more from the original source:
Rheumatoid Arthritis Stem Cell Therapy Market Highlights On Future Development 2018 to 2028 - TechnoWeekly

Objective:To ascertain the role of platelet glycoprotein Ib alpha chain (GPIb) plasma protein levels in cardiovascular, autoimmune and autoinflammatory diseases and whether its effects are mediated by platelet count.

Methods:We performed a two-sample Mendelian randomization (MR) study, using both cis and trans-acting protein expression quantitative trait loci (pQTL) near GP1BA and BRAP genes as instruments. To assess if platelet count mediated the effect, we then performed a two-step MR study. Putative associations (GPIb/ platelet count/ disease) detected by MR analyses were subsequently assessed using multiple-trait-colocalization analyses.

Results:After correcting for multiple testing (P 210-3), GPIb, instrumented by either cis-pQTL or trans-pQTL, was causally implicated with increased risk of juvenile idiopathic arthritis (JIA oligoarticular and rheumatoid factor negative subtypes). These effects of GPIb appear to be mediated by platelet count and are supported by strong evidence of colocalization (probability of all three traits sharing a common causal variant 0.80). GPIb instrumented by cis-pQTL did not appear to affect cardiovascular risk, although the GPIb trans-pQTL associates with increased risk of cardiovascular diseases and autoimmune diseases but decreased risk of autoinflammatory diseases, suggesting this trans- instrument acts through other pathways.

Conclusion:The role of platelets in thrombosis is well-established, however our findings provided some novel genetic evidence that platelets may be causally implicated in the development of JIA, and GPIba as a putative therapeutic target for these JIA subtypes.

Visit link:
Platelet glycoprotein Ib alpha chain as a putative therapeutic target for juvenile idiopathic arthritis: a Mendelian randomization study - DocWire...

Arthritis affects over 350 million people in the world.

It is also a leading cause of disability and can affect mobility and interrupt peoples ability to perform simple daily tasks.

World Arthritis Day was on October 12, which aimed to raise awareness about rheumatic and musculoskeletal diseases. Although strides have been made to find suitable treatments, many continue to suffer from debilitating pain.

Owner and founder of The Harvest Table, Catherine Clark, said there are natural remedies which can help manage symptoms associated with arthritis.

There is no cure for arthritis, but if you support your body with the right foods and supplements, you can alleviate some of the pain so that it doesnt become a hindrance in your daily life, said Clark.

Clark added that arthritis can affect ones energy levels, cause pain, and is a direct result of a loss of collagen in the bones.

ALSO READ:

Affinity Health shares how smoking may affect your surgery

The key is to find solutions that will help you feel less fatigued, while also managing pain and replenishing the collagen lost, she said. Clark offers three natural remedies to manage arthritis pain:

Anti-inflammatory foodsArthritis fatigue is real, and according to the Arthritis Foundation, unchecked inflammation and pain largely contribute to your energy levels, along with certain medications that can cause drowsiness.Boosting your energy starts with nourishing your body with the right foods, especially those with high anti-inflammatory properties that help your bodies repair process. This will not only alleviate pain but will reduce the inflammation in your body. To effectively manage your arthritis, reduce the amounts of processed foods and saturated fats as these will only further contribute to your symptoms. Instead, choose fresh fruits and vegetables, especially green vegetables and berries. Also include fish and nuts, which both contain high anti-inflammatory properties.

Slow and gentle movementMovement is a critical part of recovery when addressing the symptoms of arthritis as it retains the suppleness of your joints. Various low impact movements can specifically tackle flexibility, strength and generally support your joints to prevent injury. Prolonged lack of movement can lead to chronic stiffness that results into joint immobility which will impact your ability to complete daily activities. Yoga is an effective solution as it reduces joint pain and also eases stress, tension and promotes better quality sleep.

Collagen-rich supplementsCollagen consists of protein building blocks, otherwise known as amino acids, which aid in cushioning our joints. When you have arthritis, this cushioning diminishes which then affects your cartilage and leads to your bones rubbing against each other without protection. Supplements like Bone Broth and Collagen granules help replenish the collagen content in your body. Bone Broth is a natural anti-inflammatory, so when you have it as part of your diet, you benefit in more ways than one. Collagen granules can help reduce both osteoarthritis and rheumatoid arthritis joint pain, improve flexibility, and helps form new bones. Although all the collagen you ingest does not go straight to your bones, increasing your intake makes them readily available for your body tissues.

Natural remedies are meant to support your body so that you can better manage pain and other symptoms associated with arthritis.

The idea is to implement small and manageable changes that contribute to you feeling better and having the energy and ability to get through the day without pain getting in the way, Clark concludes.

Have a story?

Contact the newsroom by emailing:Editor at[emailprotected],or Busi Vilakazi (Journalist)[emailprotected]Also follow us on:

Read this article:
Try these three natural remedies to manage arthritis pain - Germiston City News

The report on Septic Arthritis Treatment Marketgives an analysis of Septic Arthritis Treatment Industry dependent on angles that are significant for the market study. Factors like production, the share of the overall industry, revenue rate, regions and key players characterize an overall market study. This report gives an overview of market esteemed and its development in the coming years. It likewise predicts CAGR.

Get Free Sample on this Premium Septic Arthritis Treatment Market Research Report- https://www.affluencemarketreports.com/industry-analysis/request-sample/634631/

The report is a thorough examination of this market over the world. It offers an outline of the market including its definition, applications, key drivers, key market players, key segments, and assembling innovation. Furthermore, the research report presents factual information on the status of the market and subsequently is an important wellspring of direction for companies and individuals interested in the businesses. Also, in-depth knowledge on the company profiles, product particulars, capacity, production worth, and market shares of key players are introduced in the report.

Major Key Players in this Septic Arthritis Treatment Market Report are as follows:

Lupin Pharmaceuticals (US), F. Hoffmann-La Roche Ltd (Swtizerland), AbbVie Inc (US), Amgen Inc (US), Bristol-Myers Squibb Company (US) , Johnson & Johnson (US), Pfizer (US) ,

The Report is Segmented as Following:

With an overall methodology for information aggregation, the market situations include significant players, cost and pricing working in particular geographies. Statistical looking over-utilized are SWOT Analysis, PESTLE analysis, prescient examination, and constant examination. Charts are plainly used to help the data format for a clear understanding of facts and figures.

Get COVID-19 Impact Analysis on this Premium Septic Arthritis Treatment Market Reports- https://www.affluencemarketreports.com/industry-analysis/covid19-request/634631/

The report further explains on the restraining elements in the Septic Arthritis Treatment market for individuals, strategists, and partners to deliberately execute their techniques and accomplish their objectives. Whats more, the Septic Arthritis Treatment market is segmented based on product, innovation, and end-user. This Septic Arthritis Treatment Research report segments are altogether concentrated to offer key data like open doors for business owners, planners, and marketing staff. It encourages them to deal with their activities and execute unequivocal to earn more profits. Septic Arthritis Treatment Report offers insights on each segment and sub-segment for assisting producers to identify key opportunities and grow their business.

Report Highlights

If you have any Query on this research report ask our experts- https://www.affluencemarketreports.com/industry-analysis/request-inquiry/634631/

About Us:

Affluence Market Reports is the next generation of all your research needs with a strong grapple on the worldwide market for industries, organizations, and governments. Our aim is to deliver exemplary reports that meet the definite needs of clients, which offers an adequate business technique, planning, and competitive landscape for new and existing industries that will develop your business needs.

We provide a premium in-depth statistical approach, a 360-degree market view that includes detailed segmentation, key trends, strategic recommendations, growth figures, Cost Analysis, new progress, evolving technologies, and forecasts by authentic agencies.

Contact Us:

Affluence Market Reports

Contact Person: Mr. Rohit

Phone: (US) +1-(424) 256-1722

[emailprotected]

Website: http://www.affluencemarketreports.com

Original post:
Septic Arthritis Treatment Market 2020| Know The Latest Trends, Business Outlook, New Opportunities By Top Key Player | Affluence Market Reports -...

VANCOUVER, BC, Oct. 23, 2020 /CNW/ -Precision Nanosystems, Inc. (PNI), a global leader in technologies and solutions in genetic medicine, announced today that it has received a commitment of up to $18.2 million in support from the Government of Canada under the Innovation, Science and Economic Development's (ISED) Strategic Innovation Fund (SIF) to develop a COVID-19 vaccine. PNI will use the investment to advance a best-in-class COVID-19 mRNA vaccine candidate to clinical trials.

PNI provides over 250 industry and academic partners with solutions for the development of vaccines, gene therapies, and cell therapies, in the areas of infectious diseases, oncology and rare diseases. With this investment from the Government of Canada, PNI's Chief Scientific Officer, Dr. Andrew Geall, and his team will use their state-of-the-art technology platforms and expertise in self-amplifying mRNA vectors, lipid-based drug delivery systems and nanomedicine manufacturing to develop a cost-effective COVID-19 vaccine.

As part of Canada's efforts to combat COVID-19, the Strategic Innovation Fund is working diligently to support projects led by the private sector for COVID-19 related vaccine and therapy clinical trials to advance Canada's medical countermeasures in the fight against COVID-19. "An effective vaccine will be critical as we work to contain the COVID-19 virus and prevent future infections.Today's contribution will support PNI to advance the development of a mRNA vaccine candidate through pre-clinical studies and clinical trials to help protect Canadians," stated the Honourable Navdeep Bains, Minister of Innovation, Science and Industry.

Bringing together its proprietary technology platforms, key partnerships and unparalleled expertise in nanomedicines, PNI is excited to be leading the development of a Made-in-Canada COVID vaccine. James Taylor, CEO and co-founder of PNI said "Since its inception PNI has executed on its mission to accelerate the creation of transformative medicines. It is an honour to be supported by the Canadian government in this global fight against COVID-19 and to further build capabilities for rapid response against COVID-19 and future pandemics"

About Precision NanoSystems Inc. (PNI)

PNI is a global leader in ushering in the next wave of genetic medicines in infectious diseases, cancer and rare diseases. We work with the world's leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine.PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genetic medicines.

SOURCE Precision Nanosystems

For further information: Jane Alleva, Global Marketing Manager, Precision NanoSystems, Phone: 1 888 618 0031, ext 140, mobile 1 778 877 5473

http://www.precisionnanosystems.com

See original here:
Precision NanoSystems Receives $18.2 Million from the Government of Canada to Develop an RNA Vaccine for COVID-19 - Canada NewsWire

Its a day of firsts, with the launch of two new Cambridge, Mass.-based life sciences companies, Be Biopharma, with a focus on B cell malignancies, and AavantiBio, a gene therapy company aimed at treating rare genetic diseases.

AavantiBio launched with a $107 million Series A financing round, which includes not only a $15 million equity investment from Sarepta Therapeutics, but also an experienced executive in Alexander Bo Cumbo to helm the startup. The companys lead asset is a gene therapy treatment for Friedreichs Ataxia (FA), a rare inherited genetic disease that causes cardiac and central nervous system dysfunction.

AavantiBios gene therapy builds on the work of its co-founders, renowned gene therapy researchers Barry Byrne and Manuela Corti, who have researched FA and other genetic disorders. In addition to the foundational work of Byrne and Corti, the startup will also benefit from strategic partnerships with the University of Floridas renowned Powell Gene Therapy Center and the MDA Care Center at UF Health where Byrne and Corti maintain their research and clinical practices.

Cumbo, who spent eight years at Sarepta as chief commercial officer, will serve as the first chief executive officer of AavantiBio. He said his time at Sarepta has been incredibly rewarding as that company emerged as a pioneer in treating Duchenne muscular dystrophy and limb-girdle muscular dystrophy patients and ultimately transformed into a genetic medicine leader.

It has been a privilege to contribute to this growth and play a role in serving these communities. As I look ahead to the bright future of AavantiBio and the exciting opportunity to lead this innovative company, this same dedication to serving unmet patient needs and to leveraging deep scientific expertise will be core to our mission. I am also thrilled to continue to collaborate with the talented team at Sarepta, said Cumbo, who will continue to serve as an adviser to Sarepta through the end of 2020.

Sarepta CEO Doug Ingram praised Cumbos work over the past eight years and said he built a first-in-class rare disease commercial organization. As a partner with AavantiBio, Ingram said he looks forward to a continued relationship with Cumbo and AavantiBios efforts to advance therapies for FA and other rare diseases.

In addition to Sarepta, AavantiBios Series A was supported by Perceptive Advisors, Bain Capital Life Sciences and RA Capital Management.

Be Biopharma launched with a $52 million Series A financing round. The company will use the funds to engineer B cells to treat a range of diseases. B cells are prolific protein producers that can be collected from peripheral blood, have a programmable lifetime that could last decades, can target specific tissues, and have broad, customizable functionality.

The company intends to build on the work of co-founders David Rawlings and Richard James conducted at Seattle Childrens Research Institute. Rawlings said the goal is to build new class of engineered B cell medicines that will provide direct control over the power of humoral immunity and transform the prognosis for patients who currently have limited treatment options.

Be Biopharma is helmed by David Steinberg, a co-founder of the company and a partner at Longwood Fund, one of the supporters of the Series A.

Be Bio is capitalizing on the unique attributes of B cells to create a new category of medicine that is distinct from traditional cell or gene therapy. B cells can be engineered to express a wide variety of proteins, have the potential to generate durable responses, and can be dose-titrated and administered multiple times without the need for toxic preconditioning, Steinberg said in a statement. Moreover, the varied functions of B cells suggest that B cell medicines can address a range of conditions including autoimmune diseases, cancer, and monogenic disorders, as well as enhance the immune response to infectious pathogens. We believe Be Bio is at the forefront of a new approach to fighting disease.

In addition to Longwood Fund, the Series A financing round was supported by investment leaders Atlas Venture and RA Capital Management. Alta Partners and Takeda Ventures also supported the financing round.

See original here:
Be Biopharma, AavantiBio Launch With Millions in Financing to Support Therapeutic Goals - BioSpace